Фармакоэпидемиологическое исследование употребления бета-адреноблокаторов в Украине

O. Ya. Mishchenko; V. Yu. Adonkina; I. V. Chynush

doi:10.14739/2310-1210.2012.6.20118

Authors

O. Ya. Mishchenko
V. Yu. Adonkina
I. V. Chynush

DOI:

https://doi.org/10.14739/2310-1210.2012.6.20118

Keywords:

бета-блокаторы, артериальная гипертензия, потребление, АТС/DDD-методология

Abstract

In this article the results of study of the β-adrenoblockers consumption taking into concideration three parameters - the number of sold packages, money equivalent and the DDDs/1000/d - are given. By the number of sold packages the consumption of β-adrenoblockers is varied slightly during
2008-2010.As for DDDs/1000/d - the part of β-blockers in total consumption of the fi rst line antihypertensive drugs in Ukraine is more than 16% and it is comparable to that in the European countries. For last years the consumption of the most safe selective β1-adrenoblockers has been increasing compared with non-selective drugs, but the consumption of “new” products with strong vasodilating properties (carvedilol and nebivolol) is low.

References

Прикладная фармакоэкономика: 1. учебное пособие / Под ред.В.И. Петрова. – М.: ГЭОТАР-Медиа, 2005. – 336 с.

Серцево-судинні захворювання. Рекомендації з діагностики, профілактики та лікування / За ред. В.М. Коваленка, М.І.Лутая. – К.: МОРІОН, 2011. – 408 с.

Фармакоэкономика: учебное пособие для студентов вузов /

[Л.В. Яковлева, Н.В. Бездетко, О.А. Герасимова и др.] – Х.:

НФаУ, 2007. – 176 с. 4. Центр медичної статистики (2007).

Показники здоров’я населення та використання ресурсів охорони здоров’я в Україні за 2005–2006 роки. Міністерство охорони здоров’я України.– К., 2007. – С. 86–91.

An overview of the meta-analysis of the hypertension treatment trials / M. Moser, P. Hebert, C.R. Hennekens // Archives of Internal Medicine – 1991. – V. 151. – P. 1277–1279.

Anatomical therapeutic Chemical (ATC) classifi cation index including defi ned daily doses (DDDs) for plain substances / WHO // Collaborating Centre for Drug Statistics Methodology. – 1999. – P. 23–33.

Blood pressure and stroke: an overview of published reviews /

C.M. Lawes, D.A. Bennet, V.L. Feigin at el. // Stroke. – 2004. – V. 35. – P. 776–785.

Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review / P. Rasbid, J. Leonardi-Bee, P. Bath // Stroke. – 2003. – V. 34. – P. 2741–2748.

Fretheim A. International variation in prescribing antihypertensive drugs: Its extent and possible explanations / A. Fretheim, A.D. Oxman // BMC Health Services Research. – 2005. – V. 5. – P. 21–31.

Nebivolol (nebilet) a beta-blocker of the third generation – also fore patients with obstructive lung diseases? / H. Matthys, V. Giehelhaus, J. Von Fallois // Z. Cardiol. – 2001. – V. 90 (10). – P. 760–765.

Neil B. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration / B. Neil // Lancet. – 2000. – V. 3555 (9246). – P. 1955–1964.

Prevention of cardiovascular events with an antihypertensive

regimen of amlodipine adding perindopril as required versus

atenolol adding bendrofl umethiazide as required in the Anglo-

Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering

Arm (ASCOT-BPLA): a multicenter randomized controlled trial

for ASCOT investigators / D.Dahlof, P.S. Sever, N.R. Poulter et al. // Lancet. – 2005. – V. 366. – P. 895–906.

Wright J.M. Choosing a fi rst-line drug in the management of elevated blood pressure: What is the evidence? 2: β-Blockers / J.M. Wright // CMAJ. – 2000. – V. 163(2). – P. 188–192.